UNSPSC 51382400: Nonsteroidal anti inflammatory benzophenones

Nonsteroidal anti inflammatory drugs made from compounds sometimes called benzoylbenzenes, which are based on (C6H5)2CO.

UNSPSC 51382400 Nonsteroidal anti inflammatory benzophenones (Class) shows minimal alignment between its code name and the work actually being solicited under it in recent state and local opportunities. The three recent solicitations tagged to this code—Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and Minnesota's cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—involve pharmaceutical supply, emergency medical countermeasures, and pharmacy benefit program administration rather than nonsteroidal anti-inflammatory benzophenone compounds specifically. State and local buyers using this code are sourcing emergency response medications, establishing pharmacy benefit contracts, and building multi-state cooperative purchasing frameworks for generic pharmaceuticals and over-the-counter products, but the code's nominal scope does not accurately capture this activity.

Issuing bodies include a county health department (Seminole County, Florida), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing alliance (Minnesota MMCAP, administered by the Minnesota Department of Administration). The geographic spread spans Florida, Texas, and Minnesota with participation from Oregon through the cooperative vehicle. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries due by July 26, 2023 (note: the posted date of June 30, 2026 conflicts with the response date, creating ambiguity on the actual solicitation timeline); Texas HHS's RFI on direct-to-manufacturer prescription capabilities posted April 3, 2026; and Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, distributed through three authorized wholesalers with contracts effective July 1, 2026. The code shows little relevant recent activity when matched to its stated scope of nonsteroidal anti-inflammatory benzophenones.